U.S. Antiviral Drugs Market Size & Outlook, 2022-2030
U.S. antiviral drugs market, 2018-2030 (US$M)
Related Markets
U.S. antiviral drugs market highlights
- The U.S. antiviral drugs market generated a revenue of USD 27,990.4 million in 2022 and is expected to reach USD 23,613.2 million by 2030.
- The U.S. market is expected to grow at a CAGR of -2.1% from 2023 to 2030.
- In terms of segment, hiv was the largest revenue generating application in 2022.
- Herpes is the most lucrative application segment registering the fastest growth during the forecast period.
Antiviral drugs market data book summary
| Market revenue in 2022 | USD 27,990.4 million |
| Market revenue in 2030 | USD 23,613.2 million |
| Growth rate | -2.1% (CAGR from 2022 to 2030) |
| Largest segment | Hiv |
| Fastest growing segment | Herpes |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | HIV, Hepatitis, Herpes, Influenza |
| Key market players worldwide | Roche Holding AG, GSK PLC ADR, AbbVie Inc, Merck & Co Inc, Johnson & Johnson, Bristol-Myers Squibb Co, Dr Reddy's Laboratories Ltd ADR, Aurobindo Pharma |
Other key industry trends
- In terms of revenue, U.S. accounted for 38.4% of the global antiviral drugs market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. antiviral drugs market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 2,061.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antiviral Drugs Market Scope
Antiviral Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. antiviral drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antiviral drugs market will help companies and investors design strategic landscapes.
Hiv was the largest segment with a revenue share of 34.3% in 2022. Horizon Databook has segmented the U.S. antiviral drugs market based on hiv, hepatitis, herpes, influenza covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. accounted for the major revenue share of the antiviral drugs market in 2022. Rapid technological advancements, recent U.S. FDA approvals for antiviral drugs, and intense competition between companies are expected to boost the market over the forecast period.
For instance, in March 2023, Pfizer Inc. entered into a research collaboration with Emory University to advance and develop novel antiviral agents. In May 2023, Pfizer, Inc. received FDA approval for PAXLOVID, an oral treatment for COVID-19. Moreover, in November 2020, Amneal Pharmaceuticals, Inc. received FDA approval for acyclovir cream, a generic Zovirax version.
Furthermore, supportive government initiatives for vaccination and research activities are propelling the growth of the country’s market. In addition, the regulatory and reimbursement landscape is continuously evolving to adapt to the fast-paced research progress in this sector.
Reasons to subscribe to U.S. antiviral drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. antiviral drugs market databook
-
Our clientele includes a mix of antiviral drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. antiviral drugs market , including forecasts for subscribers. This country databook contains high-level insights into U.S. antiviral drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. antiviral drugs market size, by application, 2018-2030 (US$M)
U.S. Antiviral Drugs Market Outlook Share, 2022 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
